Professor | Xianjun Qu | Asia Growth Partners

Upload Avatar (500 x 500)

Name

Xianjun Qu

Contact Information

quxj@ccmu.edu.cn

Language ability

Chinese, English

Province

Beijing

University/Lab Affiliation and Title	Capital Medical University
Faculty	Basic Medical Sciences
Academic Background & Achievements	Studied at Shandong Medical University and Shandong University Director of the Institute of New Drug Pharmacology at Shandong University Director of the Drug Screening Sub-platform of the Shandong New Drug Creation Platform Director of the China Office of Drug Discovery Therapeutics and BioScience Trends Collaborated with universities such as Tokai University, University of Tokyo, University of New South Wales, and University of Bath Signed a long-term cancer research cooperation agreement with McGill University Principal investigator for 8 major research projects funded by the National Natural Science Foundation Received 3 national new drug certificates (anti-gastric cancer drugs) Transferred a new drug production license (anti-cancer drug Tegafur, awarded the National Science and Technology Progress Award Second Prize)
Work Experience	Director of the Institute of New Drug Pharmacology at Shandong University Director of the Drug Screening Sub-platform of the Shandong New Drug Creation Platform Director of the China Office of Drug Discovery Therapeutics and BioScience Trends
Awards	National Science and Technology Progress Award Second Prize: Anti-cancer drug Tegafur

University/Lab Affiliation and Title

Capital Medical University

Faculty

Basic Medical Sciences

Academic Background & Achievements

Studied at Shandong Medical University and Shandong University
Director of the Institute of New Drug Pharmacology at Shandong University
Director of the Drug Screening Sub-platform of the Shandong New Drug Creation Platform
Director of the China Office of Drug Discovery Therapeutics and BioScience Trends
Collaborated with universities such as Tokai University, University of Tokyo, University of New South Wales, and University of Bath
Signed a long-term cancer research cooperation agreement with McGill University
Principal investigator for 8 major research projects funded by the National Natural Science Foundation
Received 3 national new drug certificates (anti-gastric cancer drugs)
Transferred a new drug production license (anti-cancer drug Tegafur, awarded the National Science and Technology Progress Award Second Prize)

Work Experience

Director of the Institute of New Drug Pharmacology at Shandong University
Director of the Drug Screening Sub-platform of the Shandong New Drug Creation Platform
Director of the China Office of Drug Discovery Therapeutics and BioScience Trends

Awards

National Science and Technology Progress Award Second Prize: Anti-cancer drug Tegafur

Areas of Focus	Tumor Pharmacology Tumor Pathogenesis and New Drug Discovery

Areas of Focus

Tumor Pharmacology
Tumor Pathogenesis and New Drug Discovery

Tumor Pharmacology Pathogenesis Drug Discovery Cancer Signaling Pathways Chronic Colitis Colon Cancer Liver Cancer Metastasis

Ying Zhao - Peking University

Kailong Li - Peking University

Wenhua Yu - Peking University

View All

Personal Information